Search research articles
Contact Us
Filters
Showing results (21-30 of 82) with videos related to
Page
of 9
Sort By:
Diabetes, Obesity & Metabolism
|
June 12, 2018
Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use
Yasuo Terauchi, Matthew C Riddle, Takahisa Hirose, et al.
Diabetes Research and Clinical Practice
|
November 12, 2016
Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)
Munehide Matsuhisa, Masayoshi Koyama, Xi Cheng, et al.
Diabetes Care
|
September 7, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, et al.
Diabetes Care
|
January 29, 2005
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
Hans U Janka, Gerd Plewe, Matthew C Riddle, et al.
Diabetes Care
|
June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes, Obesity & Metabolism
|
May 13, 2022
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
Edward Franek, Hertzel C Gerstein, Matthew C Riddle, et al.
Obstetrics and Gynecology International
|
June 12, 2012
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
Jacques Lepercq, Jay Lin, Gillian C Hall, et al.
Diabetes, Obesity & Metabolism
|
June 30, 2017
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes, Obesity & Metabolism
|
August 31, 2018
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen
Geremia B Bolli, Carol Wysham, Miles Fisher, et al.
Diabetes Care
|
April 9, 2013
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Matthew C Riddle, Thomas Forst, Ronnie Aronson, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 82) with videos related to
Sort By:
Page
of 9
Diabetes, Obesity & Metabolism
|
June 12, 2018
Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use
Yasuo Terauchi, Matthew C Riddle, Takahisa Hirose, et al.
Diabetes Research and Clinical Practice
|
November 12, 2016
Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)
Munehide Matsuhisa, Masayoshi Koyama, Xi Cheng, et al.
Diabetes Care
|
September 7, 2014
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, et al.
Diabetes Care
|
January 29, 2005
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
Hans U Janka, Gerd Plewe, Matthew C Riddle, et al.
Diabetes Care
|
June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes, Obesity & Metabolism
|
May 13, 2022
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
Edward Franek, Hertzel C Gerstein, Matthew C Riddle, et al.
Obstetrics and Gynecology International
|
June 12, 2012
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
Jacques Lepercq, Jay Lin, Gillian C Hall, et al.
Diabetes, Obesity & Metabolism
|
June 30, 2017
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.
Diabetes, Obesity & Metabolism
|
August 31, 2018
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen
Geremia B Bolli, Carol Wysham, Miles Fisher, et al.
Diabetes Care
|
April 9, 2013
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Matthew C Riddle, Thomas Forst, Ronnie Aronson, et al.
Page
of 9